Protara Therapeutics clinical trials we track

Check company identity source

Phase 3 1 trial

Phase 2 / 3 1 trial

Phase 2 2 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002 Measure: Cohort A: Incidence of high-grade Complete Response at any time by subgroup (BCG naive and BCG exposed > 24 months) according to central pathology after treatment with TARA-002. After: Measure: Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002.

Primary completion date changed

Before: May 2030. After: Oct 2031.

Check registry source